Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 26Paclitaxel 22Oxaliplatin 20Nivolumab 16Docetaxel 16Capecitabine 16Cisplatin 15Fluorouracil 11Cyclophosphamide 11fludarabine 10S 1 (combination) 10Trastuzumab 9Irinotecan 9Carboplatin 8Leucovorin 7tislelizumab 6aldesleukin 5Ramucirumab 5Interleukin-2 5Gemcitabine 5Drug Therapy 5Bevacizumab 5sintilimab 4fludarabine phosphate 4apatinib 4Radiotherapy 4Everolimus 4regorafenib 3olaparib 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Stomach Neoplasms × futibatinib × Clear all
NCT02052778 2025-03-27

A Study of TAS-120 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1/2 Completed
407 enrolled 45 charts 1 FDA
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡